Moreover, to identify the efficacy of Nb‐TriTE that dual‐targeting PD‐L1 and HLA‐G for the treatment of NSCLC tumors with variations in PD‐L1 and HLA‐G expression, a tumor heterogeneity PBMC‐CDX‐NSG murine model was conducted by inoculating ovPD‐L1/ovHLA‐G A549 cells into mice. This evidence concerns the gene HLA-G and neoplasm.